Liège, Belgium, March 14, 2023 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that following of the Company’s first and second drawdowns under the loan facility entered into with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and jointly with Highbridge , each a “Lender”), a new part of the loans was provided in kind by Highbridge against the issue of new shares.
On August 8, 2022, the Company and the Lenders entered into a three-year senior convertible loan agreement for a maximum amount of EUR 100 million, which can be drawn in three tranches. The first tranche of EUR 50 million was drawn upon signature of the agreement. The second tranche of EUR 25 million was drawn on October 31, 2022.
Following the first and second drawdowns, a new part of the loans (including accrued interest, if any, and the option prepayment amount) was contributed in kind for a total amount of EUR 1,854,570.72 through the issue of 482,528 new shares at an issue price of approximately EUR 3.84 per share. Following the last contribution in kind, the remaining principal amount of the loans already drawn amounts to EUR 48,860,161.29.